AR070977A2 - Compuesto (1r)-1-[({(2r)-2-amino-3-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-3-oxopropil}ditio)metil]-2-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-2-oxoetilamina y sus sales, proceso para su preparacion, composicion farmaceutica y - Google Patents
Compuesto (1r)-1-[({(2r)-2-amino-3-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-3-oxopropil}ditio)metil]-2-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-2-oxoetilamina y sus sales, proceso para su preparacion, composicion farmaceutica yInfo
- Publication number
- AR070977A2 AR070977A2 ARP090100837A ARP090100837A AR070977A2 AR 070977 A2 AR070977 A2 AR 070977A2 AR P090100837 A ARP090100837 A AR P090100837A AR P090100837 A ARP090100837 A AR P090100837A AR 070977 A2 AR070977 A2 AR 070977A2
- Authority
- AR
- Argentina
- Prior art keywords
- dihydroimidazo
- phenyl
- inhibitors
- pirazin
- anticancer agent
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 abstract 2
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 abstract 2
- 229940127084 other anti-cancer agent Drugs 0.000 abstract 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- 230000006820 DNA synthesis Effects 0.000 abstract 1
- 102000005454 Dimethylallyltranstransferase Human genes 0.000 abstract 1
- 108010006731 Dimethylallyltranstransferase Proteins 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 abstract 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 abstract 1
- 239000002168 alkylating agent Substances 0.000 abstract 1
- 229940100198 alkylating agent Drugs 0.000 abstract 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 abstract 1
- 229960001220 amsacrine Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 abstract 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000032823 cell division Effects 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 210000004292 cytoskeleton Anatomy 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 239000004052 folic acid antagonist Substances 0.000 abstract 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 abstract 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960004857 mitomycin Drugs 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 229960003048 vinblastine Drugs 0.000 abstract 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un producto que comprende por lo menos un inhibidor de Cdc25 fosfatasa en combinacion con por lo menos otro agente anticancerígeno para un uso terapéutico que es simultáneo, independiente o distribuido a lo largo del tiempo en el tratamiento del cáncer. El otro agente anticancerígeno preferentemente se selecciona entre: análogos de bases de ADN tales como 5-fluorouracilo; inhibidores de topoisomerasa Tipo I y/o II tales como por ejemplo camptotecina y sus análogos, doxorubicina o amsacrina; compuestos que interactuan con las células fusiformes tales como por ejemplo paclitaxel (Taxol); compuestos que actuan sobre el citoesqueleto tales como vinblastina; inhibidores de la senal de transduccion que pasa a través de las proteínas G heterotriméricas; inhibidores de preniltransferasa, y en particular inhibidores de farnesiltransferasa; inhibidores de quinasas ciclina-dependientes (CDKs); agentes de alquilacion tales como cisplatina; antagonistas del ácido folico tales como metotrexato; e inhibidores de la síntesis de ADN y division celular tales como mitomicina C. Otro objeto de la presente es la (1R)-1-[({(2R)-2-amino-3-[(8S)-8-(cicIohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8H)-iI]-3-oxopropil}ditio)metil]-2-[(8S)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8H)-il]-2-oxoetilamina, o una sal aceptable para uso farmacéutico de la misma, util como agente anticancerígeno.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0307649A FR2856688B1 (fr) | 2003-06-25 | 2003-06-25 | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070977A2 true AR070977A2 (es) | 2010-05-19 |
Family
ID=33515382
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102257A AR044930A1 (es) | 2003-06-25 | 2004-06-25 | Producto que comprende al menos un inhibidor de cdc25 fosfatasa en combinacion con al menos un agente anticancerigeno adicional |
| ARP090100837A AR070977A2 (es) | 2003-06-25 | 2009-03-09 | Compuesto (1r)-1-[({(2r)-2-amino-3-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-3-oxopropil}ditio)metil]-2-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-2-oxoetilamina y sus sales, proceso para su preparacion, composicion farmaceutica y |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040102257A AR044930A1 (es) | 2003-06-25 | 2004-06-25 | Producto que comprende al menos un inhibidor de cdc25 fosfatasa en combinacion con al menos un agente anticancerigeno adicional |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060281736A1 (es) |
| EP (3) | EP1641453B1 (es) |
| JP (2) | JP2007514639A (es) |
| AR (2) | AR044930A1 (es) |
| AT (1) | ATE439836T1 (es) |
| CA (1) | CA2530668A1 (es) |
| DE (1) | DE602004022674D1 (es) |
| DK (1) | DK1641453T3 (es) |
| ES (1) | ES2332137T3 (es) |
| FR (1) | FR2856688B1 (es) |
| MX (1) | MXPA06000216A (es) |
| MY (1) | MY141725A (es) |
| PL (1) | PL1641453T3 (es) |
| WO (1) | WO2005000852A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1461326E (pt) * | 2001-12-27 | 2007-10-16 | Sod Conseils Rech Applic | ''derivados de benzotiazole- e benzoxazole-4, 7- diona e sua utilização como inibidores de fosfatases cdc25'' |
| FR2834289B1 (fr) * | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
| FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| FR2877667B1 (fr) * | 2004-11-05 | 2007-03-23 | Sod Conseils Rech Applic | Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques |
| FR2879460B1 (fr) * | 2004-12-17 | 2007-02-23 | Sod Conseils Rech Applic | Associations anti-douleur comprenant un derive de dihydroimidazopyrazine |
| FR2879598B1 (fr) * | 2004-12-17 | 2007-03-30 | Sod Conseils Rech Applic | Inhibiteurs de phosphatases cdc25 |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| WO2009030620A1 (de) * | 2007-09-06 | 2009-03-12 | Basf Se | Blends aus verzweigten polyarylethern und hydrophilen polymeren |
| JP5394404B2 (ja) | 2008-02-06 | 2014-01-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤として有用な置換イミダゾピリダジン類 |
| AR077463A1 (es) | 2009-07-09 | 2011-08-31 | Irm Llc | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias |
| TR201903859T4 (tr) | 2010-11-12 | 2019-04-22 | Pharma Mar Sa | Bir antitümör antibiyotik ile kombinasyon terapisi. |
| EP3615030A1 (en) | 2017-04-24 | 2020-03-04 | Novartis AG | Therapeutic regimen of 2-amino-l-(2-(4-fluorophenyl)-3-(4-fluorophenylamino)-8,8-dimethyl-5,6-dihydroimidazo[1,2-a]pyrazin-7(8h)-yl)ethanone and combinations thereof |
| US11981645B1 (en) | 2023-10-10 | 2024-05-14 | King Faisal University | N′-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide as antimicrobial compound |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US735674A (en) * | 1902-01-29 | 1903-08-04 | William C Matthias | Sparking igniter for explosive-engines. |
| FR50000E (fr) | 1938-11-29 | 1939-09-29 | Moulin à café | |
| US5523430A (en) * | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
| US6673927B2 (en) * | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
| US6383871B1 (en) * | 1999-08-31 | 2002-05-07 | Micron Technology, Inc. | Method of forming multiple oxide thicknesses for merged memory and logic applications |
| EP1233787B8 (fr) * | 1999-11-09 | 2005-05-18 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| FR2812198B1 (fr) * | 2000-07-28 | 2008-07-18 | Sod Conseils Rech Applic | DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25 |
| CA2432417A1 (fr) * | 2000-12-20 | 2002-06-27 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R .A.S.) | Inhibiteurs de kinases dependantes des cylines (cdk) et de la glycogene synthase kinase-3 (gsk-3) |
| FR2825278A1 (fr) * | 2001-05-30 | 2002-12-06 | Sod Conseils Rech Applic | Produit comprenant du mikanolide, du dihydromikanolide ou un analogue de ceux-ci en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer |
| TW200304375A (en) * | 2001-12-06 | 2003-10-01 | Maxia Pharmaceuticals Inc | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer |
| PT1461326E (pt) * | 2001-12-27 | 2007-10-16 | Sod Conseils Rech Applic | ''derivados de benzotiazole- e benzoxazole-4, 7- diona e sua utilização como inibidores de fosfatases cdc25'' |
| FR2834289B1 (fr) * | 2001-12-27 | 2004-03-19 | Sod Conseils Rech Applic | Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques |
| FR2856688B1 (fr) * | 2003-06-25 | 2008-05-30 | Sod Conseils Rech Applic | PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX |
| FR2856686A1 (fr) * | 2003-06-25 | 2004-12-31 | Sod Conseils Rech Applic | Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation |
| JP4273056B2 (ja) * | 2004-08-12 | 2009-06-03 | 不二越機械工業株式会社 | 研磨装置 |
-
2003
- 2003-06-25 FR FR0307649A patent/FR2856688B1/fr not_active Expired - Fee Related
-
2004
- 2004-06-17 MY MYPI20042361A patent/MY141725A/en unknown
- 2004-06-24 CA CA002530668A patent/CA2530668A1/fr not_active Abandoned
- 2004-06-24 PL PL04767442T patent/PL1641453T3/pl unknown
- 2004-06-24 ES ES04767442T patent/ES2332137T3/es not_active Expired - Lifetime
- 2004-06-24 JP JP2006516322A patent/JP2007514639A/ja active Pending
- 2004-06-24 WO PCT/FR2004/001586 patent/WO2005000852A2/fr active Application Filing
- 2004-06-24 EP EP04767442A patent/EP1641453B1/fr not_active Expired - Lifetime
- 2004-06-24 MX MXPA06000216A patent/MXPA06000216A/es active IP Right Grant
- 2004-06-24 AT AT04767442T patent/ATE439836T1/de not_active IP Right Cessation
- 2004-06-24 EP EP08020152A patent/EP2335702A1/fr not_active Withdrawn
- 2004-06-24 DK DK04767442T patent/DK1641453T3/da active
- 2004-06-24 DE DE602004022674T patent/DE602004022674D1/de not_active Expired - Lifetime
- 2004-06-24 US US10/562,625 patent/US20060281736A1/en not_active Abandoned
- 2004-06-24 EP EP07006144A patent/EP1792905A1/fr not_active Withdrawn
- 2004-06-25 AR ARP040102257A patent/AR044930A1/es not_active Application Discontinuation
-
2008
- 2008-05-22 US US12/154,319 patent/US20090253685A1/en not_active Abandoned
- 2008-10-07 US US12/247,072 patent/US20090137596A1/en not_active Abandoned
-
2009
- 2009-03-09 AR ARP090100837A patent/AR070977A2/es unknown
- 2009-04-03 JP JP2009091214A patent/JP2009149694A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE439836T1 (de) | 2009-09-15 |
| AR044930A1 (es) | 2005-10-12 |
| MXPA06000216A (es) | 2006-04-11 |
| FR2856688A1 (fr) | 2004-12-31 |
| US20060281736A1 (en) | 2006-12-14 |
| MY141725A (en) | 2010-06-15 |
| FR2856688B1 (fr) | 2008-05-30 |
| JP2009149694A (ja) | 2009-07-09 |
| DE602004022674D1 (de) | 2009-10-01 |
| CA2530668A1 (fr) | 2005-01-06 |
| DK1641453T3 (da) | 2009-12-14 |
| WO2005000852A2 (fr) | 2005-01-06 |
| ES2332137T3 (es) | 2010-01-27 |
| EP1641453B1 (fr) | 2009-08-19 |
| WO2005000852A3 (fr) | 2005-06-30 |
| PL1641453T3 (pl) | 2010-01-29 |
| US20090137596A1 (en) | 2009-05-28 |
| EP1792905A1 (fr) | 2007-06-06 |
| EP2335702A1 (fr) | 2011-06-22 |
| JP2007514639A (ja) | 2007-06-07 |
| US20090253685A1 (en) | 2009-10-08 |
| EP1641453A2 (fr) | 2006-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070977A2 (es) | Compuesto (1r)-1-[({(2r)-2-amino-3-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-3-oxopropil}ditio)metil]-2-[(8s)-8-(ciclohexilmetil)-2-fenil-5,6-dihidroimidazo[1,2-a]pirazin-7(8h)-il]-2-oxoetilamina y sus sales, proceso para su preparacion, composicion farmaceutica y | |
| ES2665539T3 (es) | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 | |
| CN108283644B (zh) | 在化学疗法期间对正常细胞的瞬时保护 | |
| AR115985A1 (es) | Compuestos de pirazina y usos de los mismos | |
| JP2023129662A (ja) | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 | |
| CL2011000048A1 (es) | Compuestos derivados de 2-amino-4-oxo-l,4-dihidro-l,8-naftiridina-3-carboxamida, inhibidores de los receptores de qui$'!lsas pdgf y flt3; procedimientos de preparación; composición y combinación farmacéutica; útiles en el tratamiento de cánceres, tales como tumores líquidos, leucemia, entre otros. | |
| BR112020014160A2 (pt) | Compostos de benzamida | |
| CO2018003565A2 (es) | Compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| PA8548701A1 (es) | Azaindoles | |
| DOP2004000949A (es) | Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos | |
| ES2192877T3 (es) | 4-alquenil (y alquinil) oxindoles como inhibidores de kinasas ciclina-dependientes, en particular cdk2. | |
| JP2013538214A5 (es) | ||
| UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
| PA8557101A1 (es) | Benzimidazoles | |
| GT200500020A (es) | Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. | |
| ECSP066763A (es) | Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes | |
| Wilman | The chemistry of antitumour Agents | |
| ES2603570T3 (es) | Preparación de colonoscopia | |
| AR042977A1 (es) | Formulaciones farmaceuticas liquidas de palonosetron | |
| US20150111832A1 (en) | Pharmaceutical combination for the treatment and/or chemosensibilization of refractory tumors to anticancer drugs | |
| AR040580A1 (es) | Derivados de pirazol heterobiciclico como inhibidores de la quinasa | |
| AR057067A1 (es) | Procedimiento para preparar sales de tiotropio, sales de tiotropio como tales y composiciones farmaceuticas de las mismas | |
| UY28209A1 (es) | Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos. | |
| AR026037A1 (es) | Indolinonas sustituidas en posicion 5, su preparacion y su utilizacion como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |